Pediatric antiretroviral therapy

References

• Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr.29(5), 484–494 (2002).
   PubMed Web of Science ®Google Scholar
• Lindegren ML, Byers RH Jr, Thomas P et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA282(6), 531–538 (1999).
   PubMed Web of Science ®Google Scholar
• de Martino M, Tovo PA, Balducci M et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA284(2), 190–197 (2000).
   PubMed Web of Science ®Google Scholar
• Gortmaker SL, Hughes M, Cervia J et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N. Engl. J. Med.345(21), 1522–1528 (2001).
   PubMed Web of Science ®Google Scholar
• Judd A, Doerholt K, Tookey PA et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996–2006: planning for teenage and adult care. Clin. Infect. Dis.45(7), 918–924 (2007).
   PubMed Web of Science ®Google Scholar
• Patel K, Hernan MA, Williams PL et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin. Infect. Dis.46(4), 507–515 (2008).
   PubMed Web of Science ®Google Scholar
• Brady MT, Oleske JM, Williams PL et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J. Acquir. Immune Defic. Syndr.53(1), 86–94 (2010).
   PubMed Web of Science ®Google Scholar
• Furman PA, Fyfe JA, St Clair MH et al. Phosphorylation of 3´-azido-3´-deoxythymidine and selective interaction of the 5´-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl Acad. Sci. USA.83(21), 8333–8337 (1986).
   PubMed Web of Science ®Google Scholar
• Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother.46(3), 716–723 (2002).
   PubMed Web of Science ®Google Scholar
• Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet354(9184), 1112–1115 (1999).
   PubMed Web of Science ®Google Scholar
• de Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev.16(2), 125–157 (1996).
   PubMed Web of Science ®Google Scholar
• Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect. Dis.7(11), 733–738 (2007).
   PubMed Web of Science ®Google Scholar
• Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin. Ther.31(4), 692–704 (2009).
   PubMed Web of Science ®Google Scholar
• Konigs C, Feiterna-Sperling C, Esposito S. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive. Presented at: 16th Conference on Retroviruses and Opportunistic Infections, Montereal, Canada, 8–11 February 2009.
   Google Scholar
• Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J. Acquir. Immune Defic. Syndr.35(5), 538–539 (2004).
   PubMed Web of Science ®Google Scholar
• Lewis JS, 2nd, Terriff CM, Coulston DR, Garrison MW. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin. Ther.19(2), 187–214 (1997).
   PubMedGoogle Scholar
• Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J. Acquir. Immune Defic. Syndr.27(1), 30–34 (2001).
   PubMed Web of Science ®Google Scholar
• Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet350(9079), 713–714 (1997).
   PubMed Web of Science ®Google Scholar
• Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann. Intern. Med.127(10), 948 (1997).
   PubMed Web of Science ®Google Scholar
• Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann. Intern. Med.127(10), 947 (1997).
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet369(9569), 1261–1269 (2007).
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr.46(2), 125–133 (2007).
   PubMed Web of Science ®Google Scholar
• Wiznia A, Samson P, Acosta E et al. Safety and efficacy of raltegravir (RAL) in pediatric HIV infection. Preliminary analysis from IMPAACT P1066 [Poster]. Presented at: CROI 2009. Montreal, Canada, 8–11 February 2009.
   Google Scholar
• Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother.49(11), 4721–4732 (2005).
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet370(9581), 39–48 (2007).
   PubMed Web of Science ®Google Scholar
• Salzberger B, Daumer M, Gute P et al. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. Eur. J. Med. Res.12(3), 93–102 (2007).
   PubMed Web of Science ®Google Scholar
• Church JA, Cunningham C, Hughes M et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr. Infect. Dis. J.21(7), 653–659 (2002).
   PubMed Web of Science ®Google Scholar
• Menson EN, Walker AS, Sharland M et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort study. Br. Med. J.332(7551), 1183–1187 (2006).
   PubMedGoogle Scholar
• Paediatric European Network for Treatment of AIDS. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. AIDS12(14), F151–F160 (1998).
   Google Scholar
• McKinney RE Jr, Johnson GM, Stanley K et al. A randomized study of combined zidovudine–lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J. Pediatr.133(4), 500–508 (1998).
   PubMed Web of Science ®Google Scholar
• Resino S, Resino R, Micheloud D et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin. Infect. Dis.42(6), 862–869 (2006).
   PubMed Web of Science ®Google Scholar
• Gibb DM, Duong T, Tookey PA et al. Decline in mortality, AIDS and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Br. Med. J.327(7422), 1019 (2003).
   PubMed Web of Science ®Google Scholar
• McConnell MS, Byers RH, Frederick T et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989–2001. J. Acquir. Immune Defic. Syndr.38(4), 488–494 (2005).
   PubMed Web of Science ®Google Scholar
• Nachman SA, Lindsey JC, Moye J et al. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr. Infect. Dis. J.24(4), 352–357 (2005).
   PubMed Web of Science ®Google Scholar
• Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr. Infect. Dis. J.22(7), 635–641 (2003).
   PubMedGoogle Scholar
• Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin. Infect. Dis.39(5), 725–731 (2004).
   PubMed Web of Science ®Google Scholar
• Persaud D, Siberry GK, Ahonkhai A et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J. Virol.78(2), 968–979 (2004).
   PubMedGoogle Scholar
• Pomerantz RJ. Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. AIDS15(10), 1201–1211 (2001).
   PubMed Web of Science ®Google Scholar
• Saitoh A, Hsia K, Fenton T et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J. Infect. Dis.185(10), 1409–1416 (2002).
   PubMedGoogle Scholar
• Diaz C, Hanson C, Cooper ER et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol.18(3), 221–228 (1998).
   PubMedGoogle Scholar
• Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet364(9441), 1236–1243 (2004).
   PubMed Web of Science ®Google Scholar
• Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet362(9396), 1605–1611 (2003).
   PubMed Web of Science ®Google Scholar
• Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med.359(21), 2233–2244 (2008).
   PubMed Web of Science ®Google Scholar
• Abrams EJ, Wiener J, Carter R et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS17(6), 867–877 (2003).
   PubMedGoogle Scholar
• Dunn D, Woodburn P, Duong T et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J. Infect. Dis.197(3), 398–404 (2008).
   PubMed Web of Science ®Google Scholar
• HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS20(9), 1289–1294 (2006).
   PubMed Web of Science ®Google Scholar
• Wongsawat J, Puthanakit T, Kanjanavanit S et al. CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J.29(10), 966–968 (2010).
   PubMedGoogle Scholar
• Hecht FM, Grant RM. Resistance testing in drug-naive HIV-infected patients: is it time? Clin. Infect. Dis.41(9), 1324–1325 (2005).
   PubMedGoogle Scholar
• Persaud D, Palumbo P, Ziemniak C et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J. Infect. Dis.195(10), 1402–1410 (2007).
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med.354(3), 251–260 (2006).
   PubMed Web of Science ®Google Scholar
• Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev.15(2), 247–277 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med.17(5), 138–145 (2009).
   PubMedGoogle Scholar
• Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2004. Top. HIV Med.12(4), 119–124 (2004).
   PubMedGoogle Scholar
• DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis.39(7), 1038–1046 (2004).
   PubMed Web of Science ®Google Scholar
• Green H, Gibb DM, Walker AS et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS21(8), 947–955 (2007).
   PubMed Web of Science ®Google Scholar
• Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir. Ther.15(3), 297–305 (2010).
   PubMedGoogle Scholar
• Bergshoeff A, Burger D, Verweij C et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir. Ther.10(2), 239–246 (2005).
   PubMedGoogle Scholar
• Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358(6), 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Hill A, Sawyer W. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med.10(9), 527–535 (2009).
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC et al. Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy. N. Engl. J. Med.361(23), 2230–2240 (2009).
   PubMed Web of Science ®Google Scholar
• McKinney RE Jr, Rodman J, Hu C et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics120(2), e416–e423 (2007).
   PubMed Web of Science ®Google Scholar
• Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res. Hum. Retroviruses.16(5), 415–421 (2000).
   PubMedGoogle Scholar
• Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigano A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J. Acquir. Immune Defic. Syndr.40(4), 448–450 (2005).
   PubMed Web of Science ®Google Scholar
• Hazra R, Balis FM, Tullio AN et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob. Agents Chemother.48(1), 124–129 (2004).
   PubMed Web of Science ®Google Scholar
• Gafni RI, Hazra R, Reynolds JC et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics118(3), e711–e718 (2006).
   PubMed Web of Science ®Google Scholar
• Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J. Pediatr.152(4), 582–584 (2008).
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pozniak AL, Gallant JE et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J. Acquir. Immune Defic. Syndr.47(1), 74–78 (2008).
   PubMed Web of Science ®Google Scholar
• Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr. Nephrol.21(7), 1034–1036 (2006).
   PubMed Web of Science ®Google Scholar
• Judd A, Boyd KL, Stohr W et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS24(4), 525–534 (2010).
   PubMed Web of Science ®Google Scholar
• Papaleo A, Warszawski J, Salomon R et al. Increased β-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr. Infect. Dis. J.26(10), 949–951 (2007).
   PubMed Web of Science ®Google Scholar
• Van Dyke RB, Wang L, Williams PL. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J. Infect. Dis.198(11), 1599–1608 (2008).
   PubMed Web of Science ®Google Scholar
• Falco V, Rodriguez D, Ribera E et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin. Infect. Dis.34(6), 838–846 (2002).
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS16(18), 2447–2454 (2002).
   PubMed Web of Science ®Google Scholar
• Shafer RW, Smeaton LM, Robbins GK et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med.349(24), 2304–2315 (2003).
   PubMed Web of Science ®Google Scholar
• Blanco F, Garcia-Benayas T, Jose de la Cruz J, Gonzalez-Lahoz J, Soriano V. First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin. Trials4(1), 11–19 (2003).
   PubMed Web of Science ®Google Scholar
• Balestre E, Dupon M, Capdepont S et al. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. J. Clin. Virol.36(2), 95–99 (2006).
   PubMedGoogle Scholar
• Gallant JE, Rodriguez AE, Weinberg WG et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis.192(11), 1921–1930 (2005).
   PubMed Web of Science ®Google Scholar
• Gerstoft J, Kirk O, Obel N et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS17(14), 2045–2052 (2003).
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med.350(18), 1850–1861 (2004).
   PubMed Web of Science ®Google Scholar
• Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir df. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8–11 February 2004.
   Google Scholar
• van Leeuwen R, Katlama C, Murphy RL et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS17(7), 987–999 (2003).
   PubMed Web of Science ®Google Scholar
• Saavedra J, McCoig C, Mallory M et al. Clinical experience with triple nucleoside (NRTI) combination ZDV/3TC/abacavir (ABC) as initial therapy in HIV-infected children. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16–19 December 2001.
   Google Scholar
• Wells C, Sharland M, Smith C et al. Triple nucleoside analogue therapy with zidovudine (AZT), lamivudine (3TC) and abacavir (ABC) in the paediatric HIV london south network (PHILS-NET) cohort. Presented at: XIV International Conference on AIDS. Barcelona, Spain, 7–12 July 2002.
   Google Scholar
• Starr SE, Fletcher CV, Spector SA et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J.21(7), 659–663 (2002).
   PubMed Web of Science ®Google Scholar
• Fraaij PL, Neubert J, Bergshoeff AS et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir. Ther.9(2), 297–299 (2004).
   PubMed Web of Science ®Google Scholar
• Funk MB, Notheis G, Schuster T et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. Eur. J. Med. Res.10(12), 503–508 (2005).
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med.5(2), 105–109 (2004).
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet363(9417), 1253–1263 (2004).
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J. Acquir. Immune Defic. Syndr.35(5), 492–502 (2004).
   PubMed Web of Science ®Google Scholar
• Kamya MR, Mayanja-Kizza H, Kambugu A et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J. Acquir. Immune Defic. Syndr.46(2), 187–193 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor P, Worrell C, Steinberg SM et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics114(2), e235–e242 (2004).
   PubMed Web of Science ®Google Scholar
• Chadwick EG, Capparelli EV, Yogev R et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS22(2), 249–255 (2008).
   PubMed Web of Science ®Google Scholar
• De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. Int. J. Immunopathol. Pharmacol.18(4), 729–735 (2005).
   PubMedGoogle Scholar
• Saez-Llorens X, Violari A, Deetz CO et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J.22(3), 216–224 (2003).
   PubMed Web of Science ®Google Scholar
• Stebbing J, Nathan B, Jones R et al. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir. AIDS21(13), 1826–1828 (2007).
   PubMedGoogle Scholar
• Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers TW. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics117(3), e528–e536 (2006).
   PubMedGoogle Scholar
• Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet359(9308), 733–740 (2002).
   PubMed Web of Science ®Google Scholar
• Funk MB, Linde R, Wintergerst U et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS13(13), 1653–1658 (1999).
   PubMedGoogle Scholar
• Krogstad P, Lee S, Johnson G et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin. Infect. Dis.34(7), 991–1001 (2002).
   PubMed Web of Science ®Google Scholar
• Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature373(6510), 123–126 (1995).
   PubMed Web of Science ®Google Scholar
• Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature373(6510), 117–122 (1995).
   PubMed Web of Science ®Google Scholar
• Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science242(4882), 1168–1171 (1988).
   PubMed Web of Science ®Google Scholar
• Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science242(4882), 1171–1173 (1988).
   PubMed Web of Science ®Google Scholar
• Dykes C, Demeter LM. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin. Microbiol. Rev.20(4), 550–578 (2007).
   PubMed Web of Science ®Google Scholar
• Kijak GH, Avila MM, Salomon H. Mother-to-child transmission of drug-resistant HIV. Drug Resist. Updat.4(1), 29–37 (2001).
   PubMedGoogle Scholar
• Little SJ, Frost SD, Wong JK et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J. Virol.82(11), 5510–5518 (2008).
   PubMedGoogle Scholar
• Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med.347(6), 385–394 (2002).
   PubMed Web of Science ®Google Scholar
• Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J. Infect. Dis.201(9), 1303–1307 (2010).
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Gunthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis.47(2), 266–285 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J. Acquir. Immune Defic. Syndr.30(1), 105–110 (2002).
   PubMed Web of Science ®Google Scholar
• Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS17(4), 169–177 (2003).
   PubMed Web of Science ®Google Scholar
• Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics119(6), e1371–e1383 (2007).
   PubMed Web of Science ®Google Scholar
• Hammami N, Nostlinger C, Hoeree T, Lefevre P, Jonckheer T, Kolsteren P. Integrating adherence to highly active antiretroviral therapy into children’s daily lives: a qualitative study. Pediatrics114(5), e591–e597 (2004).
   PubMed Web of Science ®Google Scholar
• Malee K, Williams PL, Montepiedra G et al. The role of cognitive functioning in medication adherence of children and adolescents with HIV infection. J. Pediatr. Psychol.34(2), 164–175 (2009).
   PubMed Web of Science ®Google Scholar
• Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J.23(11), 1035–1041 (2004).
   PubMed Web of Science ®Google Scholar
• Marhefka SL, Tepper VJ, Brown JL, Farley JJ. Caregiver psychosocial characteristics and children’s adherence to antiretroviral therapy. AIDS Patient Care STDS20(6), 429–437 (2006).
   PubMed Web of Science ®Google Scholar
• Williams PL, Storm D, Montepiedra G et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics118(6), e1745–1757 (2006).
   PubMed Web of Science ®Google Scholar
• Merzel C, Vandevanter N, Irvine M. Adherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contexts. AIDS Patient Care STDS22(12), 977–987 (2008).
   PubMed Web of Science ®Google Scholar
• Battles HB, Wiener LS. From adolescence through young adulthood: psychosocial adjustment associated with long-term survival of HIV. J. Adolesc. Health30(3), 161–168 (2002).
   PubMed Web of Science ®Google Scholar
• Saitoh A, Foca M, Viani RM et al. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics121(3), e513–e521 (2008).
   PubMed Web of Science ®Google Scholar
• Wagner GJ, Kanouse DE, Golinelli D et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS20(9), 1295–1302 (2006).
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Watson AJ, Makredes M, Frangos JE, Kimball AB, Kvedar JC. Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring. Arch. Dermatol.145(11), 1230–1236 (2009).
   PubMed Web of Science ®Google Scholar
• Lester RT, Mills EJ, Kariri A et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials10, 87 (2009).
   PubMed Web of Science ®Google Scholar
• De Costa A, Shet A, Kumarasamy N et al. Design of a randomized trial to evaluate the influence of mobile phone reminders on adherence to first line antiretroviral treatment in South India – the HIVIND study protocol. BMC Med. Res. Methodol.10, 25 (2010).
   PubMed Web of Science ®Google Scholar
• Bikaako-Kajura W, Luyirika E, Purcell DW et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav.10(Suppl. 4), S85–S93 (2006).
   PubMed Web of Science ®Google Scholar
• Wiener L, Mellins CA, Marhefka S, Battles HB. Disclosure of an HIV diagnosis to children: history, current research, and future directions. J. Dev. Behav. Pediatr.28(2), 155–166 (2007).
   PubMed Web of Science ®Google Scholar
• Domek GJ. Debunking common barriers to pediatric HIV disclosure. J. Trop. Pediatr. DOI: 10.1093/tropej/fmq013 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Lesch A, Swartz L, Kagee A et al. Paediatric HIV/AIDS disclosure: towards a developmental and process-oriented approach. AIDS Care19(6), 811–816 (2007).
   PubMed Web of Science ®Google Scholar
• Butler AM, Williams PL, Howland LC, Storm D, Hutton N, Seage GR 3rd. Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics123(3), 935–943 (2009).
   PubMed Web of Science ®Google Scholar
• Souza E, Santos N, Valentini S, Silva G, Falbo A. Long-term follow-up outcomes of perinatally HIV-infected adolescents: infection control but school failure. J. Trop. Pediatr. (2010).
   Google Scholar
• Riekert K, Wiener L, Battles H. Prediction of psychological distress in school-age children with HIV. Child. Health Care28(3), 201–220 (1999).
   Web of Science ®Google Scholar
• Lester P, Chesney M, Cooke M et al. When the time comes to talk about HIV: factors associated with diagnostic disclosure and emotional distress in HIV-infected children. J. Acquir. Immune Defic. Syndr.31(3), 309–317 (2002).
   PubMed Web of Science ®Google Scholar
• Sherman BF, Bonanno GA, Wiener LS, Battles HB. When children tell their friends they have AIDS: possible consequences for psychological well-being and disease progression. Psychosom. Med.62(2), 238–247 (2000).
   PubMed Web of Science ®Google Scholar
• Michaud PA, Suris JC, Thomas LR, Kahlert C, Rudin C, Cheseaux JJ. To say or not to say: a qualitative study on the disclosure of their condition by human immunodeficiency virus-positive adolescents. J. Adolesc. Health44(4), 356–362 (2009).
   PubMed Web of Science ®Google Scholar
• Ezeanolue EE, Wodi AP, Patel R, Dieudonne A, Oleske JM. Sexual behaviors and procreational intentions of adolescents and young adults with perinatally acquired human immunodeficiency virus infection: experience of an urban tertiary center. J. Adolesc. Health38(6), 719–725 (2006).
   PubMed Web of Science ®Google Scholar
• Wiener LS, Battles HB, Heilman N, Sigelman CK, Pizzo PA. Factors associated with disclosure of diagnosis to children with HIV/AIDS. Pediatr. AIDS HIV Infect.7(5), 310–324 (1996).
   PubMedGoogle Scholar
• Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam. Plann. Perspect.31(6), 272–279 (1999).
   PubMedGoogle Scholar
• Mishell D. Family planning: contraception, sterilization, and pregnancy termination. In: Comprehensive Gynecology (5th Edition). Katz VL, Lentz GM, Lobo RA, Gershenson DM (Eds). Mosby Elsevier, PA, USA, 275–325 (2007).
   Google Scholar
• Mildvan D, Yarrish R, Marshak A et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J. Acquir. Immune Defic. Syndr.29(5), 471–477 (2002).
   PubMed Web of Science ®Google Scholar
• Ouellet D, Hsu A, Qian J et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol.46(2), 111–116 (1998).
   PubMed Web of Science ®Google Scholar
• Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception75(Suppl. 6), S8–S11 (2007).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J. Pediatr.129(5), 671–676 (1996).
   PubMed Web of Science ®Google Scholar
• Zhou T, Georgiev I, Wu X et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science329(5993), 811–817 (2010).
   PubMed Web of Science ®Google Scholar
• Tebas P, Stein D, Zifchak L et al. Prolonged control of viremia after transfer of autologous CD4 cells genetically modified with a lentiviral vector expressing long antisense to HIV env (VRX496). Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16–19 February 2010.
   Google Scholar
• Smith PF, Ogundele A, Forrest A et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3’,3’-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother.51(10), 3574–3581 (2007)
   PubMed Web of Science ®Google Scholar